Dallas, TX - June 1, 2023 - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME). The report, Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease, highlights the unmet needs and the companies leading innovation in this field. Companies highlighted in the report include Oculis, Ocuphire Pharma, OcuTerra, Rezolute, Roche, and Unity Biotechnology. This thematic report will serve as the foundation for Stonegate Healthcare's ongoing market intelligence in diabetic eye disease, providing valuable insights for investors and companies.
"Over the last four months, our team has interviewed dozens of companies and key opinion leaders yielding a comprehensive understanding of the development landscape," said Shiv Kapoor, co-founder of Stonegate Healthcare Partners. "We believe that the future of diabetic eye disease treatment lies beyond VEGF therapies. The therapies highlighted in the report have features such as VEGF-agnostic mechanisms of action, systemic control of disease, non-invasive administration, and the ability to be potentially preventative. This report combined with our ongoing market intelligence could become a quintessential resource for anyone seeking a current understanding of the evolving diabetic eye disease treatment landscape."
Please click here for the full report.
The Stonegate Healthcare mission is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development and Investor Outreach. The firm's research approach revolves around conducting comprehensive comparative analyses in specific medical fields in order to identify assets and technologies with the highest disruptive potential. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, enabling a current understanding of emerging disruptive technologies.
